NAD Case Reopened, But Fungi-Nail Marketer Fails Again With ‘#1 Pharmacist Recommended’ Claim
New Jersey-based Arcadia Consumer Healthcare, Inc., succeeded in reopening a 2018 National Advertising Division case involving its ‘#1 Pharmacist Recommended’ claim for the Fungi-Nail line, but failed again to convince the NAD that survey findings justify the claim.
You may also be interested in...
Marketers now can petition NAD to reopen cases if they have new studies or other data supporting ad claims that were shot down by the watchdog group previously, though the bar for re-review is high, says NAD Director Laura Brett.
Kramer Laboratories' claims for Fungi-Nail athlete's foot product referred to FDA and FTC after it refuses to comply with NAD's recommendation to modify the name. The firm, which agreed to modify packaging and commercial claims, was warned by FDA about the brand in 2005.
A study with nearly 500 patients with vitamin D levels tested within a year before receiving COVID-19 tests found subjects deficient in the nutrient had 1.77 greater chance of testing positive. Researchers say RCTs are needed to determine if broad population interventions are necessary.